Mark Eliason, MD
Dermatology · Salt Lake City, UTNPI 1891990156
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Novartis accounts for 86.7% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $1,381, more than ten times the $13 reported in 2019.
Across 13 payments — averaging $115.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$81
- Sanofi$65
- Lilly USA, LLC$26
- Pfizer$13
- AbbVie$13
What the payments were for
- Travel & lodging$86057%
- Food & beverage$55737%
- Education$815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $1,300 |
| Regeneron Healthcare Solutions, Inc. | 1 | $81 |
| Sanofi | 1 | $65 |
| Lilly USA, LLC | 1 | $26 |
| Pfizer | 1 | $13 |
| AbbVie | 1 | $13 |
How this compares
$1,498 in reported general payments places this provider in the 55th percentile of 163 dermatology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 15 | $241,126 |
| Dupixent SyringeDupilumab | 16 | $90,706 |
| Tacrolimus | 16 | $4,338 |
| Clobetasol Propionate | 45 | $1,771 |
| Triamcinolone Acetonide | 102 | $1,166 |
| Clindamycin Phosphate | 30 | $988 |
| Ketoconazole | 48 | $784 |
| Fluorouracil | 14 | $745 |
| Mupirocin | 98 | $741 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 38 | $645 |
| Metronidazole | 12 | $428 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 35 | $408 |
| Mometasone Furoate | 23 | $359 |
| Hydrocortisone | 26 | $313 |
| MethotrexateMethotrexate Sodium | 21 | $296 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Salt Lake City
- Gerald KruegerSalt Lake City$156K
- Kristina DuffinSalt Lake City$89K
- Mark TaylorSalt Lake City$58K
- Stephanie ZoneSalt Lake City$22K
- Lauren MadiganSalt Lake City$21K
- Elena HadjicharalambousSalt Lake City$9K
- Grace BrummerSalt Lake City$4K
- Megan ProutySalt Lake City$3K
- Michael SotiriouSalt Lake City$3K
- Dev SahniSalt Lake City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.